someone sent me this:
http://www.earthclinic.com/CURES/parkinsons.html#MB
There was a study about the effect on M Blue on Alzheimer. I don't suppose
any
lab would fund the research on it because there is no profit in it, the
stuff
is dirt cheap
maryse
Maryse, this just in:
Methylene Blue: Drug Safety Communication - Serious CNS Reactions Possible
When Given to Patients Taking Certain Psychiatric Medications
AUDIENCE: Emergency Medicine, Critical Care Medicine, Psychiatry
ISSUE: FDA has received reports of serious central nervous system (CNS)
reactions when the drug methylene blue is given to patients taking
psychiatric medications that work through the serotonin system of the brain
(serotonergic psychiatric medications). A list of the serotonergic psychiatric
medications that can interact with methylene blue can be found in the Drug
Safety Communication. Safety information about this potential drug interaction
and important drug usage recommendations for emergency and non-emergency
situations are being added to the drug labels for serotonergic psychiatric
medications.
BACKGROUND: Methylene blue is used to treat methemoglobinemia, vasoplegic
syndrome, ifosfamide-induced encephalopathy, and cyanide poisoning. It is
also used as a dye in therapeutic and diagnostic applications. Methylene
blue is a potent, reversible monoamine oxidase inhibitor (MAOI). Although the
exact mechanism of this drug interaction is unknown, methylene blue
inhibits the action of monoamine oxidase A — an enzyme responsible for breaking
down serotonin in the brain. It is believed that when methylene blue is given
to patients taking serotonergic psychiatric medications, high levels of
serotonin can build up in the brain, causing toxicity. This is referred to as
Serotonin Syndrome — signs and symptoms include mental changes (confusion,
hyperactivity, memory problems), muscle twitching, excessive sweating,
shivering or shaking, diarrhea, trouble with coordination and/or fever.
A separate Drug Safety Communication (DSC) is being released today for
Zyvox (linezolid) due to similar potential drug interactions with serotonergic
psychiatric medications and includes drug usage recommendations.
RECOMMENDATION: Methylene blue should generally not be given to patients
taking serotonergic drugs. However, there are some conditions that may be
life-threatening or require urgent treatment with methylene blue such as when
it is used in the emergency treatment of methemoglobinemia,
ifosfamide-induced encephalopathy, or cyanide poisoning.
Patients should not stop taking their serotonergic psychiatric medicine
without first talking to a healthcare professional. Read the Drug Safety
Communication below for other specific recommendations for Healthcare
Professionals and for Patients.
Healthcare professionals and patients are encouraged to report adverse
events or side effects related to the use of these products to the FDA's
MedWatch Safety Information and Adverse Event Reporting Program:
* Complete and submit the report Online:
_www.fda.gov/MedWatch/report.htm_ (http://www.fda.gov/MedWatch/report.htm)
* _Download form_
(http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm) or call 1-800-332-1088 to request a reporting
form, then complete and return to the address on the pre-addressed form, or
submit by fax to 1-800-FDA-0178
Read the MedWatch safety alert, including a link to the FDA Drug Safety
Communication, at:
_http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMe
dicalProducts/ucm265476.htm_
(http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265476.htm)
Tell us how we are doing:
_http://survey.foreseeresults.com/survey/display?cid=d509U9xg0gZVxkMRcoMsQg=
=&sid=link&cpp[date]=07_26_2011_1440&cpp[type]=S_
(http://survey.foreseeresults.com/survey/display?cid=d509U9xg0gZVxkMRcoMsQg==&sid=link&cpp[date]=07_26
_2011_1440&cpp[type]=S)
____________________________________
(http://www.fda.gov/)
Subscriber Services:
_Manage Preferences_
(https://public.govdelivery.com/accounts/USFDA/subscriber/edit?preferences=true#tab1) | _Unsubscribe_
(https://public.govdelivery.com/accounts/USFDA/subscriber/edit?preferences=true#tab1) | _Help
with this service_ (mailto:[log in to unmask]) Stay Connected:
(http://www.facebook.com/FDA)
(http://www.fda.gov/NewsEvents/InteractiveMedia/default.htm#micro) (http://www.youtube.com/user/USFoodandDrugAdmin)
(http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/GetEmailUpdates/default.htm
) (http://www.flickr.com/photos/fdaphotos/)
(http://fdatransparencyblog.fda.gov/)
____________________________________
This email was sent to [log in to unmask] using GovDelivery, on
behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave ·
Silver Spring, MD 20993 · 800-439-1420
(http://www.govdelivery.com/portals/powered-by)
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
